The preclinical drug testing landscape is undergoing a profound transformation. For decades, drug development has depended heavily on animal models and simple two-dimensional (2D) cell cultures to evaluate the safety and efficacy of new compounds before they reach human trials. While these traditional models have been instrumental in advancing medicine, they often fail to fully capture the complexity of human biology. As a result, many promising therapies that appear effective in animals do not perform the same way in humans, leading to high failure rates in clinical trials.
Today, however, the industry is at a turning point. The U.S. Food and Drug Administration (FDA) has taken a progressive step by encouraging the use of non-animal methods for evaluating drug safety and performance. This shift, supported by the FDA Modernization Act 2.0, reflects growing recognition that advanced in vitro systems can offer more reliable and ethical alternatives to animal testing.
This legislation represents a key milestone in modern biomedical science. For the first time, it formally acknowledges advanced cell-based systems, organoids, and organ-on-chip technologies as valid and credible alternatives for preclinical testing. These human-relevant models give researchers unprecedented ability to study human biology in a controlled, reproducible environment — generating data that are more predictive of real-world patient responses.
This change is not just about meeting new regulatory expectations; it signifies a broader movement toward science that is smarter, faster, and more humane. By adopting models that better mimic human biology, researchers can gain deeper insights, reduce costs, and improve the odds of success in clinical development. Ultimately, these advances promise to bring safer, more effective therapies to patients faster than ever before.
Why organoids are revolutionising preclinical research
For decades, 2D cell cultures and animal studies have been the backbone of preclinical testing. However, both systems have inherent limitations. 2D cultures, though simple and cost-effective, cannot replicate the complex structure or cell-to-cell interactions that occur in living tissues. Animal models, on the other hand, often differ significantly from humans in terms of genetics, physiology, and immune response — meaning that data obtained from animals do not always translate accurately to human outcomes.
This is where organoid technology is transforming the field.
Organoids are three-dimensional (3D), self-organising structures grown from stem cells or primary human tissues. Under the right laboratory conditions, these cells naturally assemble into miniature, functional versions of human organs such as the liver, lung, intestine, or brain. Unlike flat cell cultures, organoids mimic the architecture, function, and cellular diversity of real human organs — providing a far more realistic model for studying disease and testing potential therapies.
By offering a human-relevant microenvironment, organoids bring several powerful advantages:
- They enable scientists to study disease mechanisms in a setting that closely resembles actual human biology.
- They allow researchers to test drug efficacy and toxicity within specific organ systems, yielding data that are more predictive of clinical outcomes.
- They support the study of patient-specific responses, paving the way for personalised medicine and precision therapeutics.
- They reduce dependence on animal studies, aligning with both ethical considerations and evolving regulatory frameworks that promote humane science.
In essence, organoids bridge the gap between the laboratory and the clinic. They provide a window into how human tissues respond to drugs, infections, or genetic mutations — long before those drugs are tested in people. This not only improves confidence in early-stage decision-making but also reduces costly failures in later development phases.
Cellomatics’ commitment to human-relevant, predictive models
At Cellomatics, we are at the forefront of this global movement toward human-relevant science. Our mission is to help pharmaceutical and biotechnology companies make smarter, more ethical, and more informed decisions through advanced preclinical testing models that accurately reflect human biology.
We recognise that while traditional tools such as animal models and 2D cultures have provided valuable insights, they cannot fully replicate the intricate structure and function of living human tissues. To overcome these limitations, Cellomatics is actively developing and applying organoid-based and complex 3D in vitro systems that recreate the structural and functional environment of real human organs.
These next-generation models allow our scientists and partners to:
- Study complex disease mechanisms under physiologically relevant conditions.
- Evaluate drug candidates with greater confidence and accuracy.
- Generate high-quality, translational data that better predict human outcomes.
By providing such biologically relevant platforms, Cellomatics is helping bridge the gap between early discovery research and successful clinical application.
Advancing innovation through disease-specific organoid models
Building on our deep expertise in primary human cell-based systems, Cellomatics has already developed an advanced Non-Alcoholic Steatohepatitis (NASH) organoid model. This innovative platform allows researchers to investigate liver disease mechanisms in detail, test novel compounds, and assess therapeutic responses in a truly human-relevant environment.
The insights gained from this model not only deepen scientific understanding of NASH but also support pharmaceutical partners in de-risking their drug development programs. By generating early, predictive data, we help clients prioritise the most promising candidates and reduce the likelihood of late-stage failure — saving both time and resources.
Beyond liver disease, we are actively expanding our organoid and 3D model capabilities into oncology, immunology, and respiratory diseases. Our multidisciplinary team is developing customised models that capture the unique biological complexity of each therapeutic area. For example, 3D co-culture systems incorporating epithelial, immune, and stromal components enable more physiologically accurate assessments of drug efficacy, immune modulation, and toxicity.
Through this expanding portfolio, Cellomatics aims to provide our clients with cutting-edge tools that accelerate innovation while maintaining the highest standards of scientific rigour and ethical responsibility.
The move toward organoid and advanced 3D systems is not just a scientific advance — it’s also the right thing to do ethically. As the pharmaceutical industry seeks to reduce reliance on animal testing, technologies like organoids offer a way forward that balances scientific precision with humane practices.
At the same time, these models deliver significant efficiency benefits. Because organoids better reflect human biology, they generate more predictive data earlier in the development process. This allows research teams to make informed decisions sooner, potentially eliminating unsuitable compounds before expensive animal studies or clinical trials begin. The result is a faster, more cost-effective, and more reliable drug discovery pipeline.
By integrating organoid technology into preclinical testing, Cellomatics helps its partners advance research in a way that is innovative, ethical, and economically sustainable.
A vision for the future of drug discovery
As regulatory frameworks such as the FDA Modernization Act 2.0 continue to evolve, the adoption of human-relevant models will only accelerate. Organoids and other 3D systems are becoming central pillars of modern biomedical research — redefining how drugs are discovered, tested, and brought to market.
Cellomatics is proud to play a key role in this transformation. By investing in cutting-edge technologies and developing scientifically validated, reproducible organoid platforms, we are helping to shape a future in which drug discovery is more predictive, more humane, and ultimately more effective.
Our commitment is simple: to provide clients with models that are scientifically robust, ethically responsible, and clinically meaningful. We believe that by working closely with our partners, we can help accelerate the development of life-changing therapies that improve patient outcomes worldwide.
The next generation of drug discovery will not just be defined by faster timelines or lower costs — but by the ability to predict human biology more accurately than ever before. At Cellomatics, we are proud to be leading that change.
